Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct’s, ‘Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014’, provides an overview of the Hormone-Sensitive Prostate Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hormone-Sensitive Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone-Sensitive Prostate Cancer and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures... Research Beam Model: Research Beam Product ID: 142618 2000 USD New
Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014

 
  • Category : Pharmaceuticals
  • Published On : October  2014
  • Pages : 36
 
 

Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014



Summary

Global Markets Direct’s, ‘Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014’, provides an overview of the Hormone-Sensitive Prostate Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hormone-Sensitive Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone-Sensitive Prostate Cancer and special features on late-stage and discontinued projects.



Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.



The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.



Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope

- The report provides a snapshot of the global therapeutic landscape of Hormone-Sensitive Prostate Cancer

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Hormone-Sensitive Prostate Cancer and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Hormone-Sensitive Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Hormone-Sensitive Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products



Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Hormone-Sensitive Prostate Cancer

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Hormone-Sensitive Prostate Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5


Global Markets Direct Report Coverage 5

Hormone-Sensitive Prostate Cancer Overview 6

Therapeutics Development 7

Pipeline Products for Hormone-Sensitive Prostate Cancer - Overview 7

Pipeline Products for Hormone-Sensitive Prostate Cancer - Comparative Analysis 8

Hormone-Sensitive Prostate Cancer - Therapeutics under Development by Companies 9

Hormone-Sensitive Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 10

Hormone-Sensitive Prostate Cancer - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Hormone-Sensitive Prostate Cancer - Products under Development by Companies 13

Hormone-Sensitive Prostate Cancer - Products under Investigation by Universities/Institutes 14

Hormone-Sensitive Prostate Cancer - Companies Involved in Therapeutics Development 15

Ipsen S.A. 15

Ultimovacs AS 16

Hormone-Sensitive Prostate Cancer - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

Peptide Based Therapeutic Cancer Vaccine - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Vaccine to Target Prostate Specific Antigen for Hormone-Sensitive Prostate Cancer - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

STX-2171 - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

MVI-118 - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecules to Inhibit AKR1C3 for Oncology - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Hormone-Sensitive Prostate Cancer - Recent Pipeline Updates 31

Hormone-Sensitive Prostate Cancer - Dormant Projects 32

Hormone-Sensitive Prostate Cancer - Discontinued Products 33

Hormone-Sensitive Prostate Cancer - Product Development Milestones 34

Featured News & Press Releases 34

Apr 15, 2014: UK NICE guidance recommends FIRMAGON (degarelix) for the treatment of advanced hormone-dependent prostate cancer only in people with spinal metastases who present with signs or symptoms of impending spinal cord compression 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 36

Disclaimer 36



List of Tables

Number of Products under Development for Hormone-Sensitive Prostate Cancer, H2 2014 7

Number of Products under Development for Hormone-Sensitive Prostate Cancer - Comparative Analysis, H2 2014 8

Number of Products under Development by Companies, H2 2014 9

Number of Products under Investigation by Universities/Institutes, H2 2014 10

Comparative Analysis by Clinical Stage Development, H2 2014 11

Comparative Analysis by Early Stage Development, H2 2014 12

Products under Development by Companies, H2 2014 13

Products under Investigation by Universities/Institutes, H2 2014 14

Hormone-Sensitive Prostate Cancer - Pipeline by Ipsen S.A., H2 2014 15

Hormone-Sensitive Prostate Cancer - Pipeline by Ultimovacs AS, H2 2014 16

Assessment by Monotherapy Products, H2 2014 17

Number of Products by Stage and Target, H2 2014 19

Number of Products by Stage and Mechanism of Action, H2 2014 21

Number of Products by Stage and Route of Administration, H2 2014 23

Number of Products by Stage and Molecule Type, H2 2014 25

Hormone-Sensitive Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2014 31

Hormone-Sensitive Prostate Cancer - Dormant Projects, H2 2014 32

Hormone-Sensitive Prostate Cancer - Discontinued Products, H2 2014 33



List of Figures

Number of Products under Development for Hormone-Sensitive Prostate Cancer, H2 2014 7

Number of Products under Development for Hormone-Sensitive Prostate Cancer - Comparative Analysis, H2 2014 8

Number of Products under Development by Companies, H2 2014 9

Number of Products under Investigation by Universities/Institutes, H2 2014 10

Comparative Analysis by Clinical Stage Development, H2 2014 11

Comparative Analysis by Early Stage Products, H2 2014 12

Assessment by Monotherapy Products, H2 2014 17

Number of Products by Top 10 Target, H2 2014 18

Number of Products by Stage and Top 10 Target, H2 2014 19

Number of Products by Top 10 Mechanism of Action, H2 2014 20

Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 21

Number of Products by Top 10 Route of Administration, H2 2014 22

Number of Products by Stage and Top 10 Route of Administration, H2 2014 23

Number of Products by Top 10 Molecule Type, H2 2014 24

Number of Products by Stage and Top 10 Molecule Type, H2 2014 25 

List of Tables

NA 

List of Figures

NA